UNSPSC 51433923: Lacidipine

This classification denotes a calcium channel blocker with the molecular formula C26H33NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 260080034N, chemically known as 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1- biphenyl)-4-yl)methyl)- but generally known as lacidipine, which bears US NIH Compound Identifier 3961. European Medicines Agency schedules Lacidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08383MIG.

UNSPSC 51433923 Lacidipine is a Commodity code that represents a specific cardiovascular medication used primarily in emergency medical and pharmacy benefit contexts by state and local government health agencies and municipalities. State and local buyers procure this drug through competitive sealed-bid and cooperative purchasing solicitations that often bundle it with other advanced life support or generic pharmaceutical products. The issuing bodies include municipal fire and rescue departments (purchasing through city procurement offices), state health and human services agencies administering pharmacy benefit programs, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The scope of work reflects procurement of finished pharmaceutical products with strict expiration-date and shelf-life requirements, compliance with FDA standards and cGMP manufacturing practices, OSHA safety data sheet documentation, and vendor responsibility for product replacement and pickup of expired materials before contract expiration.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to be used by Tampa Fire Rescue, including lacidipine-adjacent cardiac agents such as diltiazem, with electronic bid submission by April 8, 2026, and an estimated contract value of $40,000; the award included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, with responses due March 26, 2026, requiring FDA-compliant products with NDC codes and wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract awards effective July 1, 2026.